WANDA BEARING
920002
CG MED EQUIP.
838810
SUZHOUBEARING
430418
4
COCYBER
835207
5
Guangdong Create Century Intelligent Equipment Group Corporation
300083
US Stock MarketDetailed Quotes
DCTH Delcath Systems
- 14.650
- +0.400+2.81%
Trading Feb 26 13:41 ET
530.33MMarket Cap-12.52P/E (TTM)
14.970High14.261Low82.52KVolume14.300Open14.250Pre Close1.22MTurnover0.24%Turnover RatioLossP/E (Static)36.20MShares16.43052wk High61.81P/B495.61MFloat Cap2.25052wk Low--Dividend TTM33.83MShs Float7069.999Historical High--Div YieldTTM4.98%Amplitude-9223372036.855Historical Low14.750Avg Price1Lot Size
Trending Stocks
Discussing
Widespread uptick! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. Chinese stocks l
Moomoo News Global
Feb 24 22:30
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites
Delcath Systems Stock Forum
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS ...
Delcath Systems, Inc. Announces Promising Results From Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:
- A 91% diseas...
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet